Biomarker Validation for ALS
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to develop treatments for ALS, a disease affecting nerve cells in the brain and spinal cord, and similar disorders. The researchers aim to test fluids like blood to identify biological markers that could facilitate the creation of new therapies. Individuals with ALS or related disorders, as well as healthy individuals without these diseases, can participate. Those diagnosed with ALS or a related condition, or those who are healthy with no risk of developing these disorders, might be suitable for this trial. Participants must be able and willing to follow study procedures. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research that could lead to new treatments for ALS and similar disorders.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to improve clinical trial readiness, which could streamline the process of bringing new therapies to patients faster. By refining protocols and methods, the trial seeks to address common bottlenecks in clinical research, such as patient recruitment and data collection. This effort could lead to more efficient trials, ultimately accelerating the development of innovative treatments for various conditions.
Who Is on the Research Team?
Michael Benatar
Principal Investigator
University of Miami
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Biomarker Evaluation
Participants undergo evaluation of biological-fluid-based biomarker candidates for ALS and related disorders
Follow-up
Participants are monitored for safety and effectiveness after biomarker evaluation
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Miami
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator